KR20090082428A - 경도인지장애 치료용 단일 약제로서의 ｄｍａｅ - Google Patents
경도인지장애 치료용 단일 약제로서의 ｄｍａｅ Download PDFInfo
- Publication number
- KR20090082428A KR20090082428A KR1020097010586A KR20097010586A KR20090082428A KR 20090082428 A KR20090082428 A KR 20090082428A KR 1020097010586 A KR1020097010586 A KR 1020097010586A KR 20097010586 A KR20097010586 A KR 20097010586A KR 20090082428 A KR20090082428 A KR 20090082428A
- Authority
- KR
- South Korea
- Prior art keywords
- treatment
- cognitive impairment
- mild cognitive
- dmae
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 40
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 34
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 206010012289 Dementia Diseases 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 9
- 229960002887 deanol Drugs 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 230000000971 hippocampal effect Effects 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 150000004677 hydrates Chemical class 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 9
- 206010027175 memory impairment Diseases 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 229940043131 pyroglutamate Drugs 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- VPMMJSPGZSFEAH-UHFFFAOYSA-N 2,4-diaminophenol;hydrochloride Chemical compound [Cl-].NC1=CC=C(O)C([NH3+])=C1 VPMMJSPGZSFEAH-UHFFFAOYSA-N 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- 229940049953 phenylacetate Drugs 0.000 claims description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- PXKVCJOCQWPPDT-MLWJPKLSSA-N 1-(dimethylamino)ethyl (2S)-5-oxopyrrolidine-2-carboxylate Chemical compound N1[C@@H](CCC1=O)C(=O)OC(C)N(C)C PXKVCJOCQWPPDT-MLWJPKLSSA-N 0.000 claims 1
- QSACCXVHEVWNMX-UHFFFAOYSA-N N-acetylanthranilic acid Chemical compound CC(=O)NC1=CC=CC=C1C(O)=O QSACCXVHEVWNMX-UHFFFAOYSA-N 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 230000001149 cognitive effect Effects 0.000 description 9
- 230000015654 memory Effects 0.000 description 8
- 208000028698 Cognitive impairment Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 6
- 208000026139 Memory disease Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 230000007000 age related cognitive decline Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0609548A FR2907679B1 (fr) | 2006-10-31 | 2006-10-31 | Utilisation de dmae pour le traitement de deficit cognitif leger |
| FR0609548 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090082428A true KR20090082428A (ko) | 2009-07-30 |
Family
ID=38050144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097010586A Withdrawn KR20090082428A (ko) | 2006-10-31 | 2007-10-31 | 경도인지장애 치료용 단일 약제로서의 ｄｍａｅ |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8207218B2 (https=) |
| EP (1) | EP2083814B1 (https=) |
| JP (1) | JP2010508253A (https=) |
| KR (1) | KR20090082428A (https=) |
| CN (1) | CN101528220A (https=) |
| AR (1) | AR063764A1 (https=) |
| AU (1) | AU2007316137A1 (https=) |
| BR (1) | BRPI0718263A2 (https=) |
| CA (1) | CA2667983A1 (https=) |
| FR (1) | FR2907679B1 (https=) |
| IL (1) | IL198463A0 (https=) |
| MA (1) | MA30925B1 (https=) |
| MX (1) | MX2009004682A (https=) |
| NO (1) | NO20092099L (https=) |
| RU (1) | RU2009120137A (https=) |
| TN (1) | TN2009000159A1 (https=) |
| WO (1) | WO2008053011A1 (https=) |
| ZA (1) | ZA200903626B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150157046A1 (en) * | 2013-12-10 | 2015-06-11 | Lifewave, Inc. | Nutritional product composition for the mind |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002320251A1 (en) * | 2001-07-05 | 2003-01-21 | Vital Basics, Inc. | Compositions for improving mental performance |
| US20060211721A1 (en) * | 2005-03-21 | 2006-09-21 | Roberts Alan R | Nutraceutical formulation of a cognitive enhancement system |
-
2006
- 2006-10-31 FR FR0609548A patent/FR2907679B1/fr not_active Expired - Fee Related
-
2007
- 2007-10-31 CA CA002667983A patent/CA2667983A1/fr not_active Abandoned
- 2007-10-31 CN CNA2007800401804A patent/CN101528220A/zh active Pending
- 2007-10-31 EP EP07822084A patent/EP2083814B1/fr active Active
- 2007-10-31 US US12/447,816 patent/US8207218B2/en not_active Expired - Fee Related
- 2007-10-31 MX MX2009004682A patent/MX2009004682A/es not_active Application Discontinuation
- 2007-10-31 RU RU2009120137/15A patent/RU2009120137A/ru not_active Application Discontinuation
- 2007-10-31 AR ARP070104851A patent/AR063764A1/es not_active Application Discontinuation
- 2007-10-31 KR KR1020097010586A patent/KR20090082428A/ko not_active Withdrawn
- 2007-10-31 BR BRPI0718263-5A patent/BRPI0718263A2/pt not_active IP Right Cessation
- 2007-10-31 AU AU2007316137A patent/AU2007316137A1/en not_active Abandoned
- 2007-10-31 JP JP2009533884A patent/JP2010508253A/ja not_active Withdrawn
- 2007-10-31 WO PCT/EP2007/061737 patent/WO2008053011A1/fr not_active Ceased
-
2009
- 2009-04-24 TN TNP2009000159A patent/TN2009000159A1/fr unknown
- 2009-04-30 IL IL198463A patent/IL198463A0/en unknown
- 2009-05-26 ZA ZA200903626A patent/ZA200903626B/xx unknown
- 2009-05-27 MA MA31926A patent/MA30925B1/fr unknown
- 2009-05-28 NO NO20092099A patent/NO20092099L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL198463A0 (en) | 2010-02-17 |
| US20090298908A1 (en) | 2009-12-03 |
| BRPI0718263A2 (pt) | 2014-01-07 |
| CN101528220A (zh) | 2009-09-09 |
| FR2907679A1 (fr) | 2008-05-02 |
| MA30925B1 (fr) | 2009-11-02 |
| CA2667983A1 (fr) | 2008-05-08 |
| TN2009000159A1 (fr) | 2010-10-18 |
| AU2007316137A1 (en) | 2008-05-08 |
| US8207218B2 (en) | 2012-06-26 |
| AR063764A1 (es) | 2009-02-18 |
| FR2907679B1 (fr) | 2009-10-30 |
| WO2008053011A1 (fr) | 2008-05-08 |
| RU2009120137A (ru) | 2010-12-10 |
| NO20092099L (no) | 2009-07-17 |
| EP2083814A1 (fr) | 2009-08-05 |
| MX2009004682A (es) | 2009-09-28 |
| JP2010508253A (ja) | 2010-03-18 |
| ZA200903626B (en) | 2010-07-28 |
| EP2083814B1 (fr) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cummings et al. | Physostigmine ameliorates the delusions of Alzheimer's disease | |
| Forette et al. | A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®) | |
| Sahakian et al. | A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease | |
| Agid et al. | Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type | |
| US20190255027A1 (en) | Methods of treating developmental disorders with gaboxadol | |
| Bartorelli et al. | Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease | |
| US8883814B2 (en) | Compositions and methods for enhancing brain function | |
| US20060020042A1 (en) | Memantine for the treatment of mild and mild to moderate Alzheimer's disease | |
| JP2019524834A (ja) | ビグアナイド系による発達障害の治療方法 | |
| Senin et al. | Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study | |
| US20070281961A1 (en) | Modified Compositions And Methods For Enhancing Brain Function | |
| JPS62106015A (ja) | 抗痴呆薬 | |
| CA2205940A1 (en) | Medicament comprising a carnitine derivative for treating alzheimer's disease in early-onset patients | |
| TW202038955A (zh) | 用於治療多巴胺性cns病症之ly3154207劑量療法 | |
| KR20090082428A (ko) | 경도인지장애 치료용 단일 약제로서의 ｄｍａｅ | |
| ES2197972T3 (es) | Uso darafenacina para potenciar las funciones cognitivas. | |
| Möller et al. | Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type | |
| Livingston et al. | Acetyl‐l‐carnitine in dementia | |
| Shaffer et al. | Nialamide in the treatment of alcoholism | |
| Thal | Physostigmine in Alzheimer’s disease | |
| Praveen | A Comparative Study to Evaluate the Efficacy and Safety of Levetiracetam as Add-On to Carbamazepine and Phenytoin in Focal Seizures at a Tertiary Care Hospital | |
| HK1135909A (en) | Dmae as sole agent for the treatment of mild cognitive impairment | |
| Sim | Rivastigmine: a review | |
| Baumel et al. | Nimodipine in the treatment of Alzheimer’s disease | |
| Walshe et al. | The relationship between behaviour disturbance and psychiatric diagnosis in male mentally handicapped adults resident in a long-stay unit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20090525 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |